Evaluation of Body Composition, Psychosocial Factors, and Drug-Related Problems in Relation to Clinical Progression in Cancer Patients Receiving Immune Checkpoint Inhibitors

What this Trial Is About

Researchers are studying how body composition, psychosocial factors, and drug-related problems affect clinical outcomes in cancer patients treated with immune checkpoint inhibitors. The study aims to understand how these factors relate to toxicity, treatment response, and quality of life during immunotherapy. It is an observational research led by Hacettepe University. Participants will be observed over a maximum of 6 months following the start of immune checkpoint inhibitor treatment. The study will assess body composition using CT scans taken before treatment, evaluate cachexia and psychosocial factors, and monitor drug-related problems throughout the follow-up period. No experimental treatments are administered, as this is an observational study. During the study, participants will undergo evaluations including body composition analysis, psychosocial assessments, and monitoring of drug-related issues. These assessments will help researchers measure clinical progression such as treatment toxicity and response along with quality of life. The total participation time is up to 6 months, during which data will be collected to better understand factors influencing outcomes in patients receiving immunotherapy.

Body Composition and Psychosocial Factors in ICI-Treated Cancer Patients